Tuesday, 28 October

Oral Presentations

11:15-11:30


Oral Abstract Session 02 (11:00-12:30) – Microbicides: Male Partner Engagement and Sexual Behaviors

Level 1, Meeting Room 1.60

12:00-12:15

Language, Terminology and Understanding of Anal Sex amongst VOICE Participants in Uganda, Zimbabwe and South Africa – Duby Z., Hartman M., Mahaka I., Montgomery E., Colvin C., Mensch B., Van der Straten A. [OA02.05]

Oral Abstract Session 02 (11:00-12:30) – Microbicides: Male Partner Engagement and Sexual Behaviors

Level 1, Meeting Room 1.60

12:15-12:30

Application of a Body Map Tool to Enhance Discussion of Sexual Behaviour in Women: Experiences from MTN 003D – Naidoo S., Woeber K., Munaiwa O., Etima J., Duby Z., Hartmann M., Montgomery E., Mensch B., Van der Straten A. [OA02.06]

Oral Abstract Session 02 (11:00-12:30) – Microbicides: Male Partner Engagement and Sexual Behaviors

Level 1, Meeting Room 1.60

13:30-13:45


Oral Abstract Session 09 (13:30-15:00) – Engaging, Recruiting and Retaining Trial Participants

Level 2, Meeting Room 2.40

14:15-14:30

WhatsApp!: Use of Mobile Technology in Optimizing ASPIRE Study Retention and Adherence at the Wits Reproductive Health and HIV Institute, Johannesburg – Reddy K., Rees H., Palanee T. [OA09.04]

Oral Abstract Session 09 (13:30-15:00) – Engaging, Recruiting and Retaining Trial Participants

Level 2, Meeting Room 2.40

14:45-15:00

Association of Tenofovir (TFV) Detection with Reduced Risk of Herpes Simplex Virus Type-2 (HSV-2) Acquisition in the VOICE (MTN 003) Study – Marrazzo J., Rabe L., Kelly C., Livant E., Chirenje Z.M., Richardson B., Dai J., Piper J., Hillier S.L. [OA10.06 LB]

Oral Abstract Session 10 (13:30-15:00) – Bacterial Vaginosis and HSV-2: Impact on Genital Immunity

Level 2, Roof Terrace Room
**Wednesday, 29 October**

**Oral Presentations & Poster Discussions**

11:15-11:30  
**To Give or Not to Give PK Results: An Ethical Dilemma for Researchers & Regulators in Uganda** – Etima J., Nakabiito C., Akello C.A., Kabwigu S., Nakyanzi T., Nabukeera J., Hartmann M., Montgomery E., Mensch B., Van der Straten A.  
[OA15.02]  
Oral Abstract Session 15 (11:00-12:30) – PrEP and Microbicide Adherence in Women  
Level 2, Roof Terrace Room

11:30-11:45  
**The Effect of Presentation of Pharmacokinetic (PK) Drug Results on Self-reported Study Product Adherence among VOICE Participants in Zimbabwe** – Musara P., Munaiwa O., Mahoka I., Mgodi N., Hartmann M., Levy L., Montgomery E., Grossmann C., Chirenje Z.M., Van der Straten A., Mensch B. [OA15.03]  
Oral Abstract Session 15 (11:00-12:30) – PrEP and Microbicide Adherence in Women  
Level 2, Roof Terrace Room

11:45-12:00  
Oral Abstract Session 15 (11:00-12:30) – PrEP and Microbicide Adherence in Women  
Level 2, Roof Terrace Room

12:00-12:15  
**Sex Matters: MTN-011 Phase 1 Study on the Impact of Sex on Tenofovir Gel Pharmacokinetics (PK) and Pharmacodynamics (PD)** – Herold B., Kelly C., Chen B., Salata R., Marzinke M., Dezzutti C., Levy L., Galaska Burzuk B., Piper J., Hendrix C. [OA13.05 LB]  
Oral Abstract Session 13 (11:00-12:30) – ARV Exposure and Efficacy in the Genital Tract  
Level 1, Auditorium 2

17:15-17:25  
Poster Discussion 01 (17:15 - 18:15) – Community Engagement and Advocacy  
Level 0, Hall 2, Oral Poster Room A

17:25-17:35  
**Pre-screening Strategies to Enhance Accrual and Retention in the ASPIRE trial at the Wits Reproductive Health and HIV Institute, Johannesburg** – Ramchuran P., Reddy K., Ramalo P., Maseko N., Vuma A., Gama L., Sibeko S., Duba N., Rees H., Palanee T. [PD01.02]  
Poster Discussion 01 (17:15-18:15) – Community Engagement and Advocacy  
Level 0, Hall 2, Oral Poster Room A

17:45-17:55  
**Consultation Beyond the CAB: Engaging the Greater Community in Rectal Microbicide Clinical Trial Design and Planning** – Collins C., Feuer C., Galea J., Gonzales P., Kanyemba B., Likhitwonnawut U., Lucas J., Miralles S., Perkins B., Pickett J., Saokhieo P., Wimonsate, W. [PD01.04]  
Poster Discussion 01 (17:15-18:15) – Community Engagement and Advocacy  
Level 0, Hall 2, Oral Poster Room A

**Poster Presentations** (10:00-11:00 & 17:00-18:30 - Level 0, Hall 2)

**Acute Seroconversion:**


**Community Engagement and Advocacy:**

**Managing Communication and Facilitating the Exchange of Ideas in a Large, Multi-Site Clinical Trial: Experiences from the ASPIRE Study** – Scheckter R., Schwartz K., Mayo A., Baeten J., Palanee T., Soto-Torres L., Torjesen K. [P02.01]
A Rectal Revolution Takes a Village: Developing an Educational Video about Rectal Microbicides – Collins, C. Friedland, B., Pickett, J. [P02.02]

Seven Steps to Strengthen Community Engagement in HIV Preventions Trials in Durban – Morar S., Ramjee G. [P02.03]


Bridging the Gap: Uniting Participants and Staff for Improved ASPIRE Study Metrics at Wits Reproductive Health and HIV Institute in Hillbrow – Reddy K., Rees H., Palanee T. [P02.06]

Family Planning:

Contraceptive Use and Pregnancy Incidence Among VOICE Participants in Uganda – Akello C., Bunge K., Nakabiito C., Gati B., Fowler M., Mishra A., Marrazzo J., Chirenje Z.M., Celum C., Balkus J. [P05.01]


Retention and Adherence in Trials:


Good Participatory Practices and Community Involvement:

Implementing Community Involvement in National Institutes of Health (NIH) HIV/AIDS Clinical Trials Networks – Campbell R., Siskind R., Morar N., Community Partners Training Working Group [P07.05]

Research Participants Skills Development as Peer Educators in Their Communities – Morar S., Ramjee G. [P07.06]
Thursday, 30 October

Oral Presentations & Poster Discussions

11:15-11:30
Oral Abstract Session 22 (11:00-12:30) – Cell and Tissue Models of ARVs for Prevention
Level 1, Meeting Room 1.60

14:15-14:30
Oral Abstract Session 30 (13:30-15:00) – Antibody Functions and Protection
Level 2, Roof Terrace Room

17:15-17:25
VOICE-C Participant Narratives of Rape: What They Mean for Female-Initiated HIV Prevention Products – Hartmann M., Montgomery E., Stadler J., Laborde N., Van der Straten A. [PD04.01]
Poster Discussion 04 (17:15-18:15) – Behavioral and Social Sciences
Level 0, Hall 2, Oral Poster Room A

17:35-17:45
Successfully Addressing Challenges to Implementing a Multinational SMS-Based Reminder and Data Collection System in a Biomedical HIV Prevention Trial – Brown W., Giguere R., Carballo-Díéguez A., Cranston R. [PD04.03]
Poster Discussion 04 (17:15-18:15) – Behavioral and Social Sciences
Level 0, Hall 2, Oral Poster Room A

Poster Presentations (10:00-11:00 & 17:00-18:30 - Level 0, Hall 2)

HIV Incidence and Prevalence:


Innovations in Vaccine and Microbicides Studies in Lab and Monitoring:


Strategies to Optimize Data Quality Metrics in the ASPIRE Trial at the Wits Reproductive Health and HIV Institute in Johannesburg – Ramchuran P., Reddy K., Rees H., Palanee T. [P38.08]

Participation in Trials: Willingness, Benefits and Challenges:


Reporting of Challenges to Adherence in VOICE: A Comparison of Quantitative and Qualitative Self-Reports Among Women During and After the Trial – Mensch B., Van der Straten A., Hartmann M., Cheng H., Miller B., Piper J., Levy L., Grossman C., Montgomery E. [P42.04]

Bone Mineral Density Changes among Healthy African Pre-Menopausal Women Participating in a Tenofovir-Based HIV PrEP Study – Mirembe B., Kelly C., Mgodi N., Greenspan S., Dai J., Bragg V., Piper J., Akello C., Kiweewa F., Magure T., Nakabiito C., Riddler S. [P42.05]

Sharing of Investigational Drug among Participants in the VOICE Trial – Moodley J., Vallabhjee L., Naidoo S., Moodley J., Ramjee G. [P42.06]

Pregnancy and PMTCT:


PrEP Trials: Preparing for Demos, Participant Experiences:
Perceptions and Practice of Heterosexual Anal Sex amongst VOICE Participants in Uganda, Zimbabwe and South Africa – Duby Z., Hartmann M., Montgomery E., Colvin C., Mensch B., Van der Straten A. [P46.03]

Sexually Transmitted Infections:

Uptake of HBV Vaccination and Incident HBV Infection in Women of Reproductive Age and at Risk of HIV-1 Infection in the VOICE (MTN 003) Study – Mgodi N., Kelly C., Kakayi B., Nair G., Dai J., Palanee T., Gomez, K., Marrazzo J., Piper J., Chirenje, Z.M. [P49.06]

Tenofovir Gel: Acceptability and Adherence:

Vaginal Rings: Baseline Characteristics, Impact on Condoms and Flora:

Effects of an Vaginal Ring Containing Maraviroc and or Dapivirine Worn for 28 days on the Vaginal Microflora – Rabe L., Meyn L., Chen B., Panther L., Hoesley C., Hillier S.L. [P53.04]